HFE C282Y

Two copies of HFE C282Y increase your tendency to absorb too much iron from food. Over decades, excess iron can damage the liver and pancreas, and this genotype is also linked to joint disease. Many people with two copies never develop organ damage. The result identifies inherited susceptibility, while iron studies show whether iron is accumulating.

C282Y genotyping is an established part of evaluating suspected hereditary hemochromatosis and testing relatives of someone with the condition. It can identify the genetic risk while iron blood tests are still normal, but it cannot predict exactly who will become ill. Most of the risk estimates below come from people of European ancestry.

What Your Genotype Means

You inherit one HFE gene copy from each biological parent. This test reports whether C282Y is present in neither, one or both copies.

• Two copies (homozygous): this is the main genetic cause of HFE-related hemochromatosis. It increases the risk of iron overload, but the genotype alone doesn't show that you have excess stored iron or organ damage.
• One copy (heterozygous): you're a carrier. A single C282Y copy alone usually doesn't cause clinically important iron overload. Clearly abnormal iron studies still need an explanation.
• No copies: this specific variant wasn't detected. Other HFE variants, other inherited iron disorders and acquired causes of iron overload remain possible.

H63D is a separate HFE variant and requires separate testing. If broader testing finds C282Y on one gene copy and H63D on the other, that's called compound heterozygosity. Mildly raised iron measures are more common with this combination, but serious iron overload is uncommon and often involves other genetic or liver-related risk factors.

How the Variant Lets Iron Build Up

Your body has no regulated way to excrete a large iron surplus, so it controls iron balance mainly by adjusting absorption from food. Hepcidin is a hormone made by the liver that limits iron entering the bloodstream from the gut and from cells that recycle old red blood cells.

The HFE protein helps regulate that response. Cell experiments show that C282Y disrupts the protein's structure and its normal movement to the cell surface. Human studies show that people with HFE-related hemochromatosis make too little hepcidin for the amount of iron they have, allowing continued iron absorption.

Transferrin saturation is the share of the blood's iron-carrying capacity occupied by iron. It often rises before ferritin. Ferritin helps estimate stored iron, but inflammation, liver injury and metabolic disease can raise it too. An elevated ferritin result by itself doesn't establish iron overload.

Who Carries It

C282Y is most common in people with Northern European ancestry, with substantial differences between countries and regions. In a North American screening study of nearly 100,000 adults, about 1 in 227 non-Hispanic white participants carried two copies. Homozygosity was much less common in the other ancestry groups studied, and C282Y did not explain their higher average iron measures.

Ancestry changes how likely this particular variant is to explain an iron problem. A negative result provides less reassurance about inherited iron overload when your ancestry or family history points toward other genetic causes.

Liver Disease and Liver Cancer

The liver is a major site of iron accumulation. In about 451,000 UK adults followed for a median of 8.9 years, men with two C282Y copies had about ten times the rate of primary liver cancer seen in men with neither C282Y nor H63D. The projected risk by age 75 was 7.2%, compared with 0.6%. These were estimates from follow-up data, not the proportion of all participants observed through their 75th birthday. The study did not establish an increased liver cancer risk in women, among whom there were few cases.

In Danish population cohorts of about 132,500 people, two copies were associated with roughly twice the rate of liver disease. An older pooled analysis estimated severe liver disease in about 1 in 10 male homozygotes. That estimate came from small numbers of older men and is an approximate population estimate, not an individual lifetime forecast.

Abdominal fat and alcohol add to the liver risk. Among UK homozygotes, men with a higher waist-to-hip ratio had about four times the rate of liver fibrosis or cirrhosis compared with those with a lower ratio. The corresponding estimate in women was about nine times, but it was much less precise. Fibrosis and cirrhosis describe increasing degrees of liver scarring. In an older analysis restricted to people with alcohol-related cirrhosis, carrying at least one C282Y copy was associated with about four times the odds of liver cancer. That comparison cannot be applied to otherwise healthy carriers.

Joint Damage

Over 11.5 years in UK Biobank, men with two copies were about twice as likely to receive an osteoarthritis diagnosis and about 1.8 times as likely to undergo hip replacement as men with neither C282Y nor H63D.

A Danish study also found more osteoarthritis among homozygotes whose iron, transferrin saturation or ferritin was normal or low at the time of sampling. This suggests that the joint risk isn't fully explained by those circulating iron measures. A single blood sample cannot establish lifetime iron exposure, and the study doesn't prove the cause of an individual's arthritis.

Diabetes and HbA1c

Iron accumulation can damage the pancreas and impair insulin production. In the Danish cohorts, two C282Y copies were associated with about 70% more diabetes. The association was also present in subgroups with normal baseline transferrin saturation or ferritin. A Swedish clinical cohort containing several HFE genotypes, mostly C282Y homozygotes, found about 36% more type 2 diabetes; that estimate wasn't specific to C282Y homozygosity.

HbA1c reflects blood sugar exposure over the preceding months and is affected by red blood cell biology. A 2026 Danish study found lower HbA1c despite slightly higher blood glucose in C282Y homozygotes. HbA1c was assessed in a cohort of about 20,000 people within the larger study. Findings suggested shorter red blood cell survival and other changes in the cells, but did not establish faster turnover as the sole cause of the lower HbA1c. This raises concern that HbA1c alone could underestimate blood sugar in some homozygotes.

Heart Disease, Other Cancers and Lifespan

The Danish cohorts found no clear increase in heart disease. An earlier US study of about 14,500 adults also found no clear excess of coronary disease, stroke, heart failure or death, although it included few homozygotes. Severe iron overload can damage heart muscle, but that complication is much less common in population studies than liver or joint disease.

Findings for breast and colorectal cancer conflict. An Australian cohort reported roughly doubled risks in homozygotes, while the Swedish clinical cohort found no clear increase.

Longer follow-up in UK Biobank found a 29% higher rate of death from any cause in men with two C282Y copies compared with men with neither common HFE variant. The study did not determine how much of that difference could be prevented through earlier diagnosis or treatment.

Why Outcomes Differ

Sex and age affect the chance of developing disease. In an Australian population cohort, documented iron-overload-related disease was found in about 28% of assessed male homozygotes and about 1% of female homozygotes after roughly 12 years of follow-up. The definition included several complications, not only advanced organ damage. Raised ferritin was much more common than documented disease.

Menstrual blood loss helps delay iron accumulation, and ferritin can rise after menopause. Pregnancy and breastfeeding should not be assumed to prevent overload; a study of women with C282Y homozygosity found no protective association with pregnancy history.

Women still have meaningful risk as they age. In UK Biobank, the estimated proportion with a hemochromatosis diagnosis by age 80 was about 41% of female homozygotes and 56% of male homozygotes. Women with two copies also had about 62% more liver disease than women with neither common variant. A recorded hemochromatosis diagnosis isn't the same outcome as documented organ damage, which helps explain why these figures differ from the Australian estimates.

Other genes also affect the outcome. Studies of C282Y homozygotes have linked genetic tendencies toward higher transferrin saturation to more liver complications, particularly in men. These research scores aren't established tools for choosing an individual treatment schedule.

Reducing the Risk of Complications

Phlebotomy removes blood to reduce excess stored iron and is the standard treatment for HFE-related iron overload. Starting treatment before advanced liver injury can prevent serious complications. Treatment is based on iron accumulation and your clinical situation; having two copies alone isn't a reason to begin regular blood removal.

Established joint disease often persists despite iron removal, and advanced liver scarring can leave an ongoing liver cancer risk even after iron stores fall. Reducing excess weight and limiting alcohol address additional causes of liver injury. If you have liver fibrosis or cirrhosis, avoiding alcohol is advised.

When Results Can Be Misleading

Clinical HFE genotyping is analytically reliable. In ten years of laboratory proficiency surveys, genotype errors were uncommon, but interpretation errors clustered around C282Y carriers and H63D homozygotes. Finding a risk variant and diagnosing disease are separate steps.

• Limited coverage: this test examines C282Y. It doesn't exclude other HFE changes or disorders caused by other iron-regulating genes.
• Ancestry: C282Y accounts for a much larger share of inherited iron overload in Northern European populations than in most other populations.
• Uncertain findings on broader tests: C282Y itself is well characterized. Broader sequencing can find variants whose effects are uncertain, and those findings alone don't establish a diagnosis.
• The source of DNA: tumor DNA can contain acquired changes and cannot by itself establish your inherited genotype. After a donor bone marrow or stem cell transplant, blood DNA may represent the donor; a genetics team should arrange an appropriate specimen.
• Consumer reports: a result from raw consumer DNA data or a third-party interpretation needs clinical confirmation before medical decisions are based on it.

A One-Time Result

Your inherited genotype is permanent, so an accurate clinical result does not need routine repetition. Its value comes from informing future iron monitoring and family decisions. If you have two copies without iron overload, ferritin and transferrin saturation are generally rechecked about once a year. Treatment requires a different monitoring schedule.

Decisions the Result Can Guide

Two copies support closer assessment of iron stores and possible organ effects. Persistent iron overload warrants specialist evaluation for treatment and liver scarring. An unexpected or technically uncertain genetic call can be confirmed using an independent method. Unexplained overload with one or no C282Y copies may warrant broader genetic testing after other causes have been assessed. Adult relatives may benefit from testing, and genetic counseling can help with inheritance, unexpected results and family planning.